AbbVie Showcases its Leadership in Rheumatology Research with New Data Across Multiple Inflammatory Joint Diseases at the EULAR 2022 Congress businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.
ABBVie today announced the presentation of new data on RINVOQ ® SKYRIZI ® and HUMIRA ® across multiple rheumatic diseases at the American College of Rheumatology's annual meeting to be held virtually Nov. 3-9 . A total of 38 abstracts, including two oral presentations and one plenary session presentation, will be presented from a broad range of studies in rheumatoid arthritis, psoriatic arthritis and ankylosing .
/PRNewswire/ AbbVie (NYSE: ABBV) today announced the presentation of new data on RINVOQ® (upadacitinib), SKYRIZI® (risankizumab) and HUMIRA® (adalimumab).